Please enter exact key words
AVAILABLE PROJECTS
Program Indication Target Discovery Preclinical PhaseⅠ PhaseⅡ PhaseⅢ
Antibody Therapy
Antibody Product Portfolio Cancer Multiple targets
ANTIGN-109 Cancer GnRHR
ANTICA-201 Cancer CA215
CD3XCD20 bsAb Lymphomas CD3; CD20
Anti-MUC1-Ab Solid tumor MUC1
CD3xBCMA-bsAb Multiple myeloma CD3; BCMA
Anti-CD40-7409 Cancer CD40
BioLink018 Non-Hodgkin lymphoma CD79B
Anti-CD137-6051 Cancer CD137
IGY-110 Covid-19 Spike proteins
Anti-LAG3 mAb Cancer LAG3
OX40-Ab Cancer OX40
A1801 ADC Breast cancer; Melanoma GPNMB
PMB-104 Asthma Immunoglobulin E
PMB-107 Solid tumor GARP/LAP-TGFβ1 complex
PBI-108 Solid tumor PD-1 and Siglec-15
PMB-109 Asthma TSLP
PMB-131 IgA nephropathy MASP-2
PBI-203 Solid tumor PD-L1 and VEGF
PBI-204 Sepsis Adrenomedullin
PBI-205 Solid tumor PD-1 and PD-L1
PMB-211 Fibrosis CTGF
AB0017 Hemophilia TFPI
AB0061 Hematologic malignancies CD3; CD19
BI0106 ADC Solid tumor Trop-2
ADC0320 ADC Cancer Tissue factor
SP0306 ADC Inflammatory bowel disease IL23; TL1A
BI0201 ADC Solid tumor HER2; Trop-2
BI0107 ADC Acute myeloid leukemia CLEC12A
BC0001 Dual-payload ADC Cancer EGFR
BC0002 Dual-payload ADC Cancer HER2
BC0003 Dual-payload ADC Solid tumor Trop-2
BI0109 ADC Solid tumor B7H4
BI0110 ADC Solid tumor Claudin 6
BI0112 ADC Solid tumor FGFR2b
SP0901 ADC Cancer CAIX; EGFR
Protein Therapy
APD-IL10 Solid tumor IL-10; PD-1
P75NEURO Neurological diseases p75NTR (NGFR)
P11 Type 2 diabetes GLP-1 receptor
Angiocidin Acute myeloid leukemia Death receptor 6
TT-173 Surgical bleeding and trauma
ROD-16 Hyperoxaluria
BioLink001 Solid tumor IL-15
JZ-603 Allergic asthma; Allergic rhinitis IgE
PepTRx anti-HIV AIDS HIV proteins
AP0025 NASH; MASH; SHTG FGF21
CD001 Fusion Protein Cancer PD-1; IL-21
AP-26 Fusion Protein Solid tumor PD-1; IL-2
BioLink1052 Fusion Protein Type 2 diabetes, Obesity, etc FGF21; GLP-1
CD009 Fusion Protein Solid tumor PD-L1; IL-10
Oncolytic Virotherapy
RV-scFv-PDL1 Cancer PD-L1
OV-FV-01 Cancer Confidential
BS001 Cancer
Small Molecules
IVW-1001 Dry eye disease TRPM8
Polyoxygenated Cyclohexene Compound 4 Pain Nav1.7
PPM-100 Cancer IKZF1/3
Fascin Inhibitor Cancer Fascin
Resveratrol (Micellar) Alzheimer’s disease SIRT1
NMMHC IIA Inhibitors Thrombosis NMMHC IIA
VISTA Agonist Psoriasis VISTA
Berbamine Analogues (+)ssRNA virus infections TRPML
Intravenous Anesthetics Anesthesia GABA(A) receptor
Water-soluble Taxanes Cancer Tubulin
CQ-527 Cancer Tubulin
FHND41 NSCLC EGFR
BioLink1006 Metastatic cancer EGFR
BioLink2018 B-cell lymphomas BTK
BioLink2020 Solid tumor FGFR1-3
BioLink2022 Heart failure PDE9
BioLink2024 Inflammatory diseases NLRP3
FHND91 Multiple myeloma Proteasome
FHND71 Solid tumor RET
CA0078 Osteoarthritis; Psoriasis JAK
IN1605 Autoimmune diseases, Inflammatory diseases, etc MyD88
PKY001 Solid tumor YAP/TEAD
Cell Therapy
Double Negative T Cells Acute myelocytic leukemia Multi-target
Anti-BCMA CAR-T Cell Multiple myeloma BCMA
Anti-GPRC5D CAR T-cell Multiple myeloma GPRC5D
GCC-CART Metastatic colorectal cancer GUCY2C
EDB-TCR-T Solid tumor Fibronectin extra domain B
duraCAR-T71 Cancer Claudin 18.2
TCR-T012 Cancer WT1
TCR-T013 Cancer EBV
TCR-T014 Cervical cancer HPV-16
TCR-T015 Lung cancer; Pancreatic cancer KRAS
TCR-T016 Cancer NY-ESO-1
Gene Therapy
RNA4TNBC Triple-negative breast cancer MIR34A; MIR21
Others
IVIEW-1201 Conjunctivitis
ABOUT US

Protheragen’s business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.